According to a Health Stories Project-Insights (HSPi) report, 81 percent of people believe uniform testing should be required for biosimilars and biologics.
A Specialty Pharmacy Times report says addressed topics included: “the impact of patient condition on the understanding of biosimilars; awareness and understanding of biologics and biosimilars; ability to differentiate between biologics and biosimilars; testing of biologics and biosimilars; factors that affect treatment choices; trusted sources of information; reactions to physicians switching to a biosimilar; and reactions to a pharmacy substitution of a biosimilar product.
“As biosimilars are poised for expanded adoption, we knew the time was right to ask autoimmune patients who are either already taking biologics or have conditions that could result in treatment with biologics about their understanding of, concerns about, and willingness to take biosimilars,” HSPi Vice President Jo Anne Jensen said. “Our findings were very revealing, leading us to conduct 2 follow-up forums with both biologic-experienced and biologic-naive patients. These additional in-depth discussions explored patient feelings and the factors that influence their treatment.”